Tue Mar 11 2025
Telemedicine has transformed weight loss treatments, but recent FDA changes threaten to upend the industry. Dr. Leo Damasco and Phoebe Gutierrez explore the impact of removing GLP-1 medications like tirzepatide and semaglutide from the shortage list, what it means for telehealth companies, and how providers can pivot to stay ahead.
Get AI-powered summaries and transcripts for any meeting, phone call, or podcast.
Available on iOS, Android, Mac, and Windows
No transcript available.
